This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Nimodipine
Selective L-type calcium channel blocker (CCB) with the highest BBB penetration of any clinical CCB; FDA-approved 1988 for improving…
Aliases (15)
Overview
What is Nimodipine?
Nimodipine is a dihydropyridine L-type calcium channel blocker developed by Bayer, FDA-approved for prevention of cerebral vasospasm following subarachnoid hemorrhage. Its high lipophilicity gives it preferential CNS penetration vs other CCBs.
Key Benefits
Reduces delayed ischemic neurological deficits and improves outcomes after subarachnoid hemorrhage. Off-label uses include vascular dementia, age-related cognitive decline, and as adjunctive therapy in bipolar disorder; experimental for migraine prevention.
Mechanism of Action
Selectively blocks L-type voltage-gated calcium channels (Cav1.2, Cav1.3) with preferential cerebrovascular smooth muscle action, dilating cerebral arteries. Also reduces neuronal calcium overload during ischemia, providing neuroprotection.
Pharmacokinetics
▸Brand options8 known
StatusRx (US, EU, UK, Canada, Australia); OTC in some jurisdictions (India, parts of Latin America); not WADA-prohibited as of 2026
Research Indications
NMDA receptor modulation indirectly
Ca²⁺ buffering at the postsynaptic density may indirectly dampen NMDA-mediated excitotoxicity downstream.
Anti-apoptotic
reduced mitochondrial Ca²⁺ overload preserves mPTP integrity, blocks cytochrome c release.
Anti-inflammatory
Ca²⁺ is a second messenger for NF-κB activation in microglia; reduced Ca²⁺ flux dampens neuroinflammation.
CACNA1C / mood regulation
Cav1.2 polymorphisms (CACNA1C rs1006737) are GWAS-replicated risk variants for bipolar disorder and schizophrenia. This is the rationale …
Neurogenic
some animal data suggesting promotion of adult neurogenesis via reduced Ca²⁺-induced repression of Wnt signaling. Speculative.
Research Protocols
Disclaimer: These are commonly discussed research protocols and not medical advice.
Peptide Interactions
(already in the canonical stack) — Mg²⁺ is a physiological Ca²⁺ antagonist at the cellular level (NMDA receptor blockade, vascular smooth muscle, mitochondri…
multi-target neuroprotectant including NMDA antagonism, voltage-gated Ca²⁺ channel modulation, and α2-adrenergic effects. Mechanistically additive with nimod…
Different mechanism (peptide-mimetic neurotrophic surge — BDNF/NGF/GDNF), no antagonism, complementary protection. Top-line stack rationale for users in this…
Multi-target neuroprotectant with mitochondrial preservation (PGC-1α, Mfn1), Nrf2 antioxidant, anti-platelet, anti-neuroinflammatory. NBP and nimodipine targ…
BBB-crossing CoQ10 analog supports mitochondrial electron-transport-chain function during the post-Ca²⁺-flux mitochondrial stress window. Mechanism-complemen…
(already in the canonical stack) — Membrane phospholipid substrate + cholinergic support. Different mechanism, no antagonism.
(already in the canonical stack at 2 g) — Anti-inflammatory + neuronal membrane fluidity. Standard neuroprotection foundation, no interaction.
Mitochondrial electron-cycling support (alternate ETC pathway via complex I bypass). Mechanism-complementary; layered with NBP and idebenone for full mitocho…
(canonical-stack add) — Lipid-soluble Nrf2 activator + mitochondrial membrane antioxidant. No interaction with nimodipine.
(already in the canonical stack at 1200 mg/d) — Glutathione replenishment, hepatoprotective. Useful given nimodipine's mild hepatic signal.
(already in the canonical stack) — Membrane substrate. Neutral.
No documented interaction. Both are CYP3A4 substrates; modafinil is a mild CYP3A4 inducer which would modestly *reduce* nimodipine plasma levels (the opposit…
Quality Indicators
Pharmacy-dispensed, intact packaging
Prescription tablets in original sealed packaging from a licensed pharmacy.
Generic vs branded
Generics are usually fine but bioavailability can vary slightly; track if you switch.
Unbranded blister or counterfeit risk
Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.
What to Expect
- Day 1PK-driven acute peak per administration. Verify dose tolerated.
- Week 1Steady-state reached for most daily-dosed pharma.
- Week 2-4Therapeutic effect established; titration window if needed.
- Long-termPeriodic monitoring per drug class (labs, BP, ECG as applicable).
Side Effects & Safety 9
Side Effects
- 1Hypotension / orthostatic dizziness. Most-reported side effect. Dose-dependent. For the canonical archetype (lean, low resting HR, likely lower-baseline-BP from combat-sport conditioning), this is the side-effect to watch most closely. Mitigation: start low (30 mg), AM dosing, gradual position changes, hydration, fluid + sodium adequacy.
- 2Headache (5-12%, vasodilatory pattern, typically resolves within first week)
- 3Mild GI symptoms (nausea, abdominal discomfort) — 1-5%
- 4Bradycardia (DHP CCBs are less bradycardic than verapamil/diltiazem, but possible)
- 5Lower-leg / ankle edema (DHP class effect; less than amlodipine)
- 6Mild flushing
- 7Mild rash
- 8Mild ALT/AST elevation (1-5%) — usually subclinical, reversible
- 9Constipation (CCB class effect)
When to Stop
- Severe hypotension — particularly with CYP3A4 inhibitors or other antihypertensives. Reversible on discontinuation.
- Hepatotoxicity — rare drug-induced liver injury reports; mechanism less well-characterized than NBP. Worth periodic LFT monitoring during chronic use.
- Symptomatic bradycardia / heart block — rare with DHP CCBs in healthy users; concerning if pre-existing AV node disease.
- Stevens-Johnson syndrome / severe cutaneous reactions — extremely rare class-level reports; not a documented concern at nimodipine doses.
- Reflex tachycardia — DHP CCBs can produce reflex sympathetic activation in some users. Less common with nimodipine than nifedipine.
- Withdrawal hypertension — not a documented concern at off-label doses; SAH patients tapered without rebound.
- Pulmonary edema / heart failure exacerbation — relevant in cardiac patients, not the canonical archetype.
- First 7 days of any cycle: BP monitoring at home (AM + PM, same arm, after sitting 5 min). Watch for systolic drop >15 mmHg or orthostatic drop >20 mmHg standing. If significant, dose-reduce or discontinue.
- First 30 days: ALT/AST baseline + week 4 check. Stop if ALT >3× ULN.
- Whenever any new CYP3A4 inhibitor enters the stack — recheck BP, watch for additive hypotension.
- During fight prep / weight cuts / dehydration windows — pause nimodipine. Combination of dehydration + vasodilation = orthostatic disaster.
- If symptoms of liver dysfunction develop (RUQ pain, dark urine, jaundice, severe fatigue) — discontinue immediately, recheck LFTs.
- Severe hypotension (SBP <90) — relative contraindication
- Severe hepatic impairment (Child-Pugh B/C) — dose reduction required (CYP3A4-dependent metabolism)
- Concurrent strong CYP3A4 inhibitor therapy — relative contraindication (dose reduction)
- Recent intracranial hemorrhage *outside* SAH context — case-by-case
- Pregnancy / lactation — Category C, insufficient data
- Known DHP class hypersensitivity — absolute contraindication
References
BRANT — British aneurysm nimodipine trial (BMJ 1989, Pickard et al)
n=554 SAH, foundation of FDA approval, reduced cerebral infarction and poor outcome.
View StudyAllen et al — Cerebral arterial spasm: a controlled trial of nimodipine in subarachnoid hemorrhage (NEJM 1983)
original RCT.
View StudyPetruk et al — Nimodipine treatment in poor-grade aneurysm patients (J Neurosurg 1988)
pre-FDA Canadian multicenter.
View StudyCochrane review — Calcium antagonists for aneurysmal subarachnoid haemorrhage (Dorhout Mees et al, 2007/2018)
anchor meta-analysis, RR 0.81 for poor outcome.
View StudyTollefson — Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia (Am J Psychiatry 1990 / 1993)
n=178, modest cognitive benefit at 90 mg/d.
View StudyPantoni et al — Efficacy and safety of nimodipine in subcortical vascular dementia (Stroke 2005)
n=230, MMSE benefit in imaging-stratified subgroup.
View StudyLópez-Arrieta & Birks Cochrane — Nimodipine for primary degenerative, mixed and vascular dementia (2002)
pooled mild benefit, "promising but unproven."
View StudyBailey et al — A trial of the effect of nimodipine on outcome after head injury (HIT-I, Acta Neurochir 1991)
n=176, no benefit in severe head injury.
View StudyEuropean Study Group — A multicenter trial of the efficacy of nimodipine on outcome after severe head injury (HIT-II, J Neurosurg 1994)
n=852, no overall benefit; traumatic SAH subgroup signal.
View StudyHarders et al — Traumatic subarachnoid hemorrhage and its treatment with nimodipine (HIT-III, J Neurosurg 1996)
n=123, traumatic SAH subgroup, positive.
View StudyMurray et al — Nimodipine in traumatic subarachnoid haemorrhage: HIT-IV (J Neurotrauma 2007)
n=592, halted for futility.
View StudyVergouwen et al — Effect of nimodipine on outcome in patients with traumatic subarachnoid hemorrhage: a systematic review (Lancet Neurol 2006)
meta-analysis, insufficient evidence for routine TBI use.
View StudyHeiss et al — Effect of nimodipine on regional cerebral blood flow in patients with chronic cerebrovascular disease (Stroke / J Cereb Blood Flow Metab 1994)
PET evidence of selective CBF increase in hypoperfused regions.
View StudyStriessnig et al — L-type Cav1.2 calcium channels: from in vitro findings to in vivo function (Physiol Rev 2014)
comprehensive Cav1.2 review.
View StudyDisterhoft — Nimodipine and recovery from injury (multiple aged-rabbit eyeblink papers, 1990s-2000s)
most-cited "anti-aging cognition" mechanism work.
View StudyHovda lab — Calcium-mediated injury after TBI (multiple, 1990s-2010s)
concussion neurometabolic cascade reference.
View StudyFerrari et al — The neurobiology of depression: an integrated view of key findings (Int J Clin Pract 2017)
CACNA1C in mood disorders.
View StudyPazzaglia et al — Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness (J Clin Psychopharmacol 1998)
original NIMH open-label.
View StudyManji et al — The cellular phenotype of bipolar disorder (Mol Psychiatry 2003)
CACNA1C / Cav1.2 mechanism review.
View StudyCross-Disorder Group of the Psychiatric Genomics Consortium — Identification of risk loci with shared effects on five major psychiatric disorders (Lancet 2013)
CACNA1C rs1006737 cross-disorder GWAS.
View StudyTomassoni et al — Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies (Clin Exp Hypertens 2008)
comprehensive PK + clinical review.
View StudyCarlson et al — Pharmacokinetics of nimodipine after single and multiple dosing in healthy subjects (Eur J Clin Pharmacol 1986)
PK fundamentals.
View StudyMück & Bode — Influence of CYP3A4 inhibitors on nimodipine pharmacokinetics (Eur J Clin Pharmacol 1994)
CYP3A4 interaction studies.
View StudyFDA prescribing information — Nymalize oral solution
official FDA label.
View StudyFDA Drug Shortages — historical nimodipine entries
supply disruption history.
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.